Imaging positron emission tomography

A typical 19F NMR spectrum of a compound with a trifluorovinyl group is given in Fig. 6.20. This compound is the chemical precursor of the drug known as EF5, which is used in positron emission tomography imaging to detect hypoxic tissue. 

J.H.F. Rudd, K.S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, Z.A. Fayad, Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible Implications for atherosclerosis therapy trials, J. Am. Coll. Cardiol. 50 (2007) 892-896. 

L.M. Kenny, D.M. Vigushin, A. Al-Nahhas, S. Osman, S.K. Luthra, S. Shousha, R. C. Coombes, E.O. Aboagye, Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [ F]fluorothymidine-positron emission tomography imaging Evaluation of analytical methods. Cancer Res. 65(21)... 

J.S. Fowler, N.D. Volkow, G.J. Wang, Y.S. Ding, 2-deoxy-2-[18F]fluoro-D-glucose and alternative radiotracers for positron emission tomography Imaging using the human brain as a model, Semin. Nucl. Med. 34 (2004) 112-121. 

Hypofunction of prefrontal cortex as shown by positron emission tomography imaging or cerebral blood flow determinations. Hypofrontality occurs in both medicated and unmedicated schizophrenics. The pituitary gland. Hypophysectomy is removal of the pituitary gland. 

Numerous other amino acid decarboxylases have been isolated and characterized, and much interest has been shown as a result of the irreversible nature of the reaction with the release of C02 as the thermodynamic driving force. Although these enzymes have narrow substrate-specificity profiles, their utility has been widely demonstrated. Additional industrial processes will continue to be developed once other decarboxylases become available. Such biocatalysts would include the aromatic amino acid (E.C. 4.1.1.28), phenylalanine (E.C. 4.1.1.53) and tyrosine (E.C. 4.1.1.25) decarboxylases, which likely could be used to produce derivatives of their respective substrates. These derivatives are finding increased use in the development of peptidomimetic drugs and as possible positron emission tomography imaging agents.267-268... 

In comparison to the conventional automated synthesis, the radiochemical yield and purity of the compound obtained by microreactor processing was higher and also had shorter synthesis time [21]. Multiple doses of2-deoxy-2-[18F]fluoro-D-glucose for positron emission tomography imaging studies in mice were prepared. Today, 2-deoxy-2-[18F]fluoro-D-glucose is routinely produced in about 50 min with the use of... 

Radiopharmaceuticals for Positron Emission Tomography Imaging of Somatostatin Receptor Positive Tumors... 

Frankie WG, Narendran R, Huang Y, Hwang DR, Lombardo I, et al. 2005. Serotonin transporter availability in patients with schizophrenia A positron emission tomography imaging study with [11C]DASB. Biol Psychiatry 57 1510-1516. 

Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, et al. 1986. Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 16 2-34. 

Leiserowitz L, see Weissbuch I (2005) 259 123-165 Lhotak P (2005) Anion Receptors Based on Calixarenes. 255 65-95 Li WP, Meyer LA, Anderson CJ (2005) Radiopharmaceuticals for Positron Emission Tomography Imaging of Somatostatin Receptor Positive Tumors. 252 179-192 Liang Z, see Du Q (2005) 261 45-61 Lingerfelt L, see Guiseppi-Elie A (2005) 260 161-186... 

Meyer MA. Elevated basal ganglia glucose metabolism m cyclosporme nemotoxicity a positron emission tomography imaging study. J Nemoimagmg 2002 12(l) 92-3. 

Goswami, R., Kung, M.-R, Ponde, D. E., et al. (2006) Fluoro alkyl derivatives of dihydro-tetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl. Med. Biol., 33, 685-694. 

Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ et al (2011) Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 8 1398-1403... 

UGUR, O., et al., Ga-66 labelled somatostatin analogue DOTA-Dphe -Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumours, Nucl. Med. Biol. 29 (2002) 147-157. 

Saunders CA, Dussek JE, O Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxy-glucose whole-body positron emission tomography imaging in die staging of lung cancer. Ann Thorac Surg 1999 67 790-797. 

Akhurst T, Larson SM. Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999 26 577-583. 

Kearfott KJ, Carey JE, Clemenshaw MN, Faulkner DB (1992). Radiation protection design for a clinical positron emission tomography imaging suite. Health Phys 63 581... 

Kenny, L. M., Aboagye, E.O., and Price, P.M. Positron emission tomography imaging of cell proliferation in oncology. Clin. Oncol., 16 176-185, 2004. 

Kowalski, J., Henze, M., Schuhmacher, J., Macke, H.R., Hofmann, M., and Haberkorn, U. (2003) Evaluation of positron emission tomography imaging using [ Ga]-DOTA-D Phe(l)-Tyr(3)-Octreotide in comparison to [ ln]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5, 42-48. 

Agdeppa, E.D., Kepe, V, Liu, J., Flores-Torres, S., Satyamurthy, N., Petrie, A., Cole, G.M., Small, G.W., Huang, S.C., and Barrio, J.R. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthyl-ethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer s disease, J Neu-rosci 21, RC189. 

---